Yu Mingyang, Su Yun, Cui Daping, Sun Qiang, Luan Bowu, Zhao Dewei
Department of Traumatic Orthopedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China.
Department Chemistry, Stony Brook University, NY, USA.
J Cancer Res Ther. 2016 Apr-Jun;12(2):963-8. doi: 10.4103/0973-1482.179085.
Bone metastasis (BM) is common in patients with lung cancer. Osteolysis is caused by increased osteoclast activity. Interleukin-20 (IL-20) and receptor activator of nuclear factor kappa-B ligand (RANKL) are crucial for osteoclast formation. Osteoprotegerin (OPG) inhibits a receptor activator of RANKL/RANK signaling. The aims of this study were to analyze the serum levels of IL-20, OPG, and RANKL in patients with and without BM and to observe the effect of chemotherapy on these cytokines.
A total 54 cases of pathologically confirmed lung adenocarcinoma (ADC) and 18 healthy individuals (Control) were enrolled in this study. Eligible patients were divided into three groups (18 patients per group): ADC without BM (ADC), ADC with BM (ADC + BM), and ADC with BM treated with chemotherapy (ADC + BM + Chemo). Serum IL-20, RANKL, and OPG levels were analyzed by enzyme-linked immunosorbent assay.
Serum IL-20, RANKL, and OPG levels in ADC + BM patients were significantly elevated compared with that in the Control or ADC groups (both P < 0.001). The serum cytokine levels were significantly lower following chemotherapy compared with that in patients who did not receive chemotherapy (P < 0.001).
Serum IL-20, RANKL, and OPG levels increase in patients with lung cancer and BMs. Chemotherapy suppresses the elevation of these cytokines.
骨转移（BM）在肺癌患者中很常见。骨溶解是由破骨细胞活性增加引起的。白细胞介素-20（IL-20）和核因子κB受体活化因子配体（RANKL）对破骨细胞形成至关重要。骨保护素（OPG）抑制RANKL/RANK信号的受体活化因子。本研究的目的是分析有无骨转移的肺癌患者血清中IL-20、OPG和RANKL水平，并观察化疗对这些细胞因子的影响。
本研究纳入54例经病理确诊的肺腺癌（ADC）患者和18名健康个体（对照组）。符合条件的患者分为三组（每组18例）：无骨转移的肺腺癌（ADC）组、有骨转移的肺腺癌（ADC + BM）组和接受化疗的有骨转移的肺腺癌（ADC + BM + Chemo）组。采用酶联免疫吸附测定法分析血清IL-20、RANKL和OPG水平。
与对照组或ADC组相比，ADC + BM组患者血清IL-20、RANKL和OPG水平显著升高（均P < 0.001）。与未接受化疗的患者相比，化疗后血清细胞因子水平显著降低（P < 0.001）。
肺癌合并骨转移患者血清IL-20、RANKL和OPG水平升高。化疗可抑制这些细胞因子的升高。
